These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33778426)

  • 1. Pharmacokinetic variability of factor VIII concentrates in Chinese pediatric patients with moderate or severe hemophilia A.
    Chen Z; Huang K; Li G; Zhen Y; Wu X; Di A; Liu G; Li Z; Alfonso I; Wu R
    Pediatr Investig; 2021 Mar; 5(1):38-45. PubMed ID: 33778426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic Studies of Factor VIII in Chinese Boys with Severe Hemophilia A: A Single-Center Study.
    Chen ZP; Li PJ; Li G; Tang L; Zhen YZ; Wu XY; Cheng XL; Luke KH; Blanchette VS; Poon MC; Ding QL; Wu RH
    Chin Med J (Engl); 2018 Aug; 131(15):1780-1785. PubMed ID: 29848837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced pharmacokinetics and reduced bleeds in boys with hemophilia A after switching to Kovaltry from other standard half-life factor VIII concentrates.
    Huang K; Zhen Y; Li G; Wu X; Chen Z; Wu R
    Res Pract Thromb Haemost; 2022 Feb; 6(2):e12686. PubMed ID: 35356665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative pharmacokinetics of two extended half-life FVIII concentrates (Eloctate and Adynovate) in adolescents with hemophilia A: Is there a difference?
    Carcao MD; Chelle P; Clarke E; Kim L; Tiseo L; Morfini M; Hossain T; Rand ML; Brown C; Edginton AN; Lillicrap D; Iorio A; Blanchette VS
    J Thromb Haemost; 2019 Jul; 17(7):1085-1096. PubMed ID: 31038793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Presurgical pharmacokinetic analysis of a von Willebrand factor/factor VIII (VWF/FVIII) concentrate in patients with von Willebrand's disease (VWD) has limited value in dosing for surgery.
    Di Paola J; Lethagen S; Gill J; Mannucci P; Manco-Johnson M; Bernstein J; Nichols WL; Bergman GE
    Haemophilia; 2011 Sep; 17(5):752-8. PubMed ID: 21689209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extended half-life factor VIII concentrates in adults with hemophilia A: Comparative pharmacokinetics of two products.
    Teitel J; Sholzberg M; Iorio A
    Res Pract Thromb Haemost; 2021 Feb; 5(2):349-355. PubMed ID: 33733034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
    Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
    Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Population pharmacokinetics of two recombinant human coagulation factor Ⅷ preparations in patients with hemophilia A].
    Hua BL; Chelle P; Yeung C; Gu J; Zhao YQ; Iorio A
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):673-677. PubMed ID: 31495135
    [No Abstract]   [Full Text] [Related]  

  • 9. Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.
    Swystun LL; Ogiwara K; Rawley O; Brown C; Georgescu I; Hopman W; Labarque V; Male C; Thom K; Blanchette VS; Carcao MD; Lillicrap D
    Blood; 2019 Sep; 134(11):880-891. PubMed ID: 31350267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of Kovaltry in thirty-five pediatric patients aged <12 years with severe hemophilia A.
    Huang K; Zhen Y; Li G; Wu X; Wu R; Chen Z
    Haemophilia; 2021 May; 27(3):e340-e346. PubMed ID: 33645868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of recombinant coagulation factor VIII-SingleChain in patients with severe hemophilia A.
    Zhang Y; Roberts J; Tortorici M; Veldman A; St Ledger K; Feussner A; Sidhu J
    J Thromb Haemost; 2017 Jun; 15(6):1106-1114. PubMed ID: 28244200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-evaluation of Pharmacokinetic-Guided Dosing Tools for Factor VIII.
    Preijers T; van Moort I; Fijnvandraat K; Leebeek FWG; Cnossen MH; Mathôt RAA;
    Thromb Haemost; 2018 Mar; 118(3):514-525. PubMed ID: 29534249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The influence of dead space in blood sampling needle on FVIII level and pharmacokinetic profiles in children with hemophilia.
    Zhen Y; Ai D; Huang K; Li G; Chen Z; Wu R
    Hematology; 2024 Dec; 29(1):2314871. PubMed ID: 38346146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic-Pharmacodynamic Comparison of Recombinant and Plasma-Derived von Willebrand Factor in Patients with von Willebrand Disease Type 3.
    Bauer A; Friberg-Hietala S; Smania G; Wolfsegger M
    J Blood Med; 2023; 14():399-411. PubMed ID: 37332615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between endogenous VWF:Ag and PK parameters and bleeding frequency in severe haemophilia A subjects during three-times-weekly prophylaxis with rFVIII-FS.
    Lalezari S; Martinowitz U; Windyga J; Enriquez MM; Delesen H; Schwartz L; Scharrer I
    Haemophilia; 2014 Jan; 20(1):e15-22. PubMed ID: 24252058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison Pharmacokinetic Dosing Tools in Hemophilia A Children.
    Genç CA; Gürlek Gökçebay D; Koşan Çulha V; Kaya Z; Özbek NY
    Indian J Hematol Blood Transfus; 2024 Jan; 40(1):108-115. PubMed ID: 38312178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The fraction of recombinant factor VIII:Ag unable to bind von Willebrand factor has no FVIII coagulant activity: studies in vitro.
    Ofosu FA; Tse H; Naqvi A; Bhakta H; Song Y
    Haemophilia; 2012 Nov; 18(6):917-25. PubMed ID: 22672786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current Understanding of Inherited Modifiers of FVIII Pharmacokinetic Variation.
    Swystun LL; Lillicrap D
    Pharmgenomics Pers Med; 2023; 16():239-252. PubMed ID: 36998673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factor VIII pharmacokinetics associates with genetic modifiers of VWF and FVIII clearance in an adult hemophilia A population.
    Ogiwara K; Swystun LL; Paine AS; Kepa S; Choi SJ; Rejtö J; Hopman W; Pabinger I; Lillicrap D
    J Thromb Haemost; 2021 Mar; 19(3):654-663. PubMed ID: 33219619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fixed doses of N8-GP prophylaxis maintain moderate-to-mild factor VIII levels in the majority of patients with severe hemophilia A.
    Chowdary P; Carcao M; Holme PA; Jiménez-Yuste V; Lentz SR; Møss J; Poulsen LH; Shen C; Tosetto A; Wheeler A; Santagostino E
    Res Pract Thromb Haemost; 2019 Jul; 3(3):542-554. PubMed ID: 31294338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.